2020 May 5

Discovered the physiopathological mechanisms underlying the most common pediatric Leukemia.

Researchers from the Josep Carreras Institute unveil the mechanisms that lead to hyperdiploid Acute Lymphoblastic Leukemia, Hyper D-ALL, the most common pediatric B-cell Leukaemia.

B-cell acute lymphoblastic leukemia (B-ALL) is characterized by the accumulation of abnormal immature B-cell precursors (BCP) in the bone marrow (BM) and is the most common pediatric cancer. Among the different subtypes known in B-ALL, the most common one is identified by the presence of a higher number of chromosomes than in healthy cells and is called High hyperdiploid B-ALL (HyperD-ALL). This genetic abnormality is an initiating oncogenic event affiliated to childhood B-ALL, and it remains poorly characterized.

HyperD-ALL comprises 30% of pediatric B-ALL and usually has a favorable clinical outcome, with 90% of survival in patients with this hematologic cancer. Despite this, until date, there was very little knowledge on how hyperploidy occurs in HyperD-ALL, as an initiating oncogenic event in B-ALL and which secondary alterations are necessary for leukemic B-ALL cells accumulation in the bone marrow, impeding the growth of healthy cells and leading to the clinical leukemia complications.

A precise knowledge of the physiopathological mechanisms underlying HyperD- ALL was necessary because the morbidity/mortality associated with HyperD-ALL still represents a clinical challenge due to the high number of patients suffering from this type of B-ALL. For this reason, Oscar Molina, researcher of the Group of Stem Cells Biology, Developmental Leukaemia, and Immunotherapy led by Pablo Menéndez, has led research on the mechanisms underlying HyperD-ALL, unveiling how and why it happens, published in Blood Journal.

Molina and the co-authors of the study hypothesized that the origin of the pathogenic mechanisms associated with hyperploidy in B-ALL could be in the moment during mitosis.

“We knew already that HyperD-ALL arises in a BCP in utero. However, the causal molecular mechanisms of hyperdiploidy in BCPs remained elusive. As faithful chromosome segregation is essential for maintaining the genomic integrity of cells, and deficient chromosome segregation leads to aneuploidy and cancer, we wanted to observe and deepen on what is happening in chromosomes’ segregation in HyperD-ALL, because we suspected that by studying cell division in this kind of cells we would find an explanation to this oncogenic process.”

Researchers used a large cohort of primary pediatric B-ALL samples, 54. Molina and his colleagues discovered that three key processes and actors for correct mitosis or cell division and chromosome segregation were misfunctioning in hyperdiploid cells and that artificial disruption of these processes in blood cells with normal chromosome numbers, generated hyperdiploid cells resembling those in B-ALL samples. 

The main proteins and processes leading to fatal error were a malfunctioning of the Condensin complex; the protein Aurora B kinase, responsible for a correct chromosome attachment to the spindle poles, thus ensuring proper chromosome segregation; and the mitotic checkpoint, or Spindle Assembly Checkpoint (SAC), the cell machinery involved in controlling that chromosomes are separated adequately to each pole of the cell that is dividing. 

“Next steps would be to study whether other subtypes of B-ALL with abnormal chromosome numbers, such as hypodiploid B-ALL, a very aggressive subtype of pediatric blood cancer characterized by lower numbers of chromosomes, share a common molecular mechanism. These studies will allow generating the first in vivo models of leukemias with abnormal chromosome numbers in mice that will be crucial to understand its origin and development, thus facilitating the development of more targeted and less toxic therapies for these pediatric blood cancers” stated Óscar Molina.

This research has been funded mainly by the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R), the Asociación Española Contra el Cáncer (AECC-CI-2015), and the ISCIII (PI17/01028). OM was supported by a Lady Tata Memorial Trust (2017) and a “Beatriu de Pinós” postdoctoral fellowship (2018-2019) from Generalitat de Catalunya (2016-BP00048).